Amolyt Pharma Competitors and Similar CompaniesClear all
Amolyt Pharma's competitors and similar companies include Biocon, Takeda, Shanghai Junshi Biosciences and Kyowa Kirin.
 Amolyt Pharma Amolyt Pharma (formerly known as Alizé Pharma) is a company that specializes in the development of biopharmaceutical drugs, proteins, and peptides for the treatment of metabolic diseases and cancer. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Shanghai Junshi Biosciences Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases. |  Kyowa Kirin Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. | ||
Founding Date | Founding Date 2015 | Founding Date 1978 | Founding Date 1781 | Founding Date 2012 | Founding Date 2008 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Écully, FR HQ Cambridge, US | Locations Bengaluru, IN HQ Bengaluru, IN Nanakramguda, IN Dublin, IE Kuala Lumpur, MY Puchong, MY Delémont, CH see more | Locations Shanghai, CN HQ | ||
Employees | Employees 373% decrease | Employees 16,5612% increase | Employees 47,4554% decrease | Employees 2,578 | Employees 5,669 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 43.7 b | Valuation ($) N/A | Valuation ($) 8.8 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ₹167.8b (FY, 2026) | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) ¥2.4b (FY, 2025) | Revenue (est.) ¥496.8b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods ₹56.9b (FY, 2026) | Cost of goods ¥818.8b (FY, 2025) | Cost of goods ¥466.5m (FY, 2025) | Cost of goods ¥114.3b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit ₹115.8b (FY, 2026) | Gross profit ¥3.8t (FY, 2025) | Gross profit ¥2b (FY, 2025) | Gross profit ¥383.4b (FY, 2025) |
Net income | Net income N/A | Net income ₹3.7b (FY, 2026) | Net income ¥108.1b (FY, 2025) | Net income (¥1b) (FY, 2025) | Net income ¥67b (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 93.1m | Total funding raised N/A | Total funding raised $ 57.8m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Biocon
HQ
Bengaluru, IN
Employees
16,561↑ 2% increase
Biocon is a company that develops and manufactures biopharmaceutical products.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View companyShanghai Junshi Biosciences
HQ
Shanghai, CN
Employees
2,578
Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.
View companyKyowa Kirin
HQ
Tokyo, JP
Employees
5,669
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system.
View company